Navigation Links
Lexicon Presents LX4211 Clinical Data at European Association for the Study of Diabetes Annual Meeting
Date:9/13/2011

tic and commercial potential of LX4211. This press release also contains forward-looking statements relating to Lexicon's growth and future operating results, discovery and development of products, strategic alliances and intellectual property, as well as other matters that are not historical facts or information.  All forward-looking statements are based on management's current assumptions and expectations and involve risks, uncertainties and other important factors, specifically including those relating to Lexicon's ability to successfully conduct clinical development of LX4211 and preclinical and clinical development of its other potential drug candidates, advance additional candidates into preclinical and clinical development, obtain necessary regulatory approvals, achieve its operational objectives, obtain patent protection for its discoveries and establish strategic alliances, as well as additional factors relating to manufacturing, intellectual property rights, and the therapeutic or commercial value of its drug candidates, that may cause Lexicon's actual results to be materially different from any future results expressed or implied by such forward-looking statements.  Unless specifically indicated otherwise, results reported as trends were not statistically significant. Information identifying such important factors is contained under "Risk Factors" in Lexicon's annual report on Form 10-K for the year ended December 31, 2010, as filed with the Securities and Exchange Commission.  Lexicon undertakes no obligation to update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE Lexicon Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine technology :

1. Lexicon Pharmaceuticals to Present at Morgan Stanley Global Healthcare Conference
2. Lexicon Pharmaceuticals to Present at Stifel Nicolaus Healthcare Conference
3. Lexicon Pharmaceuticals to Present at the Wedbush 2011 Life Sciences Management Access Conference
4. Lexicon Announces Publication of Results From the Phase 2 Trial of LX1031 in Patients With Irritable Bowel Syndrome in Journal of Gastroenterology
5. Phase 2 Trial of Lexicons LX1032, Telotristat Etiprate, Shows Positive Results in Carcinoid Syndrome
6. Lexicon Pharmaceuticals Reports on Clinical Program Status and 2011 Second Quarter Results
7. Lexicons IBS Drug Candidate, LX1033, Successfully Completes Phase 1 Clinical Trial
8. Lexicon Presents LX4211 Mechanism of Action Data at American Diabetes Association Meeting and Announces Commencement of Phase 2b Clinical Trial in Type 2 Diabetes
9. Lexicon Pharmaceuticals Announces Webcast of 2011 Annual R&D Day
10. Lexicon Pharmaceuticals Reports on Clinical Program Status and 2011 First Quarter Results
11. Lexicon to Provide First Quarter 2011 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... , May 23, 2013  Texas, premier physician ... deliver doctors the survival tools they need to provide ... in today,s health care marketplace. "I am ... save local practices," said Stephen L. Brotherton ... (TMA). " Texas doctors are determined ...
(Date:5/23/2013)... 23, 2013   Direct to implant, or ... an appropriate option for many women with BRCA ... their breast cancer risk, or with breast cancer. ... and a second surgery to insert permanent implants, ... surgery as mastectomy can be a medically and ...
(Date:5/23/2013)...  BioElectronics Corporation (OTC Pink: BIEL), the maker of ... FDA panel meeting for non-thermal shortwave diathermy: ... Therapy Meeting was held on May 21, 2013 in ... of the meeting was very narrow, in that the ... the application of non-thermal shortwave diathermy for the treatment ...
Breaking Medicine Technology:TMA Launches Physician Services Organization for Patient Care 2TMA Launches Physician Services Organization for Patient Care 3TMA Launches Physician Services Organization for Patient Care 4Direct to Implant ("One Step") Mastectomy Breast Reconstruction Reduces Number of Surgeries and Time to Final Cosmetic Results 2Direct to Implant ("One Step") Mastectomy Breast Reconstruction Reduces Number of Surgeries and Time to Final Cosmetic Results 3BioElectronics and Pulsed Shortwave Therapy Make Progress 2
... Data presented,today at a major medical meeting found ... five days is as,effective as standard therapy of ... of complicated urinary tract infections,(cUTI) and acute pyelonephritis ... LEVAQUIN in the,U.S., presented the data during a ...
... Pressure in Obese and,Non-Obese Hypertensive Patients, CHICAGO, ... today presented positive data from two clinical,studies ... selective beta,1-blocker with vasodilating properties currently under ... (FDA) for the treatment of,hypertension. Data from ...
Cached Medicine Technology:Five Days of LEVAQUIN(R) as Effective as 10 Days of Ciprofloxacin,in Complicated Urinary Tract Infections and Acute Pyelonephritis 2Five Days of LEVAQUIN(R) as Effective as 10 Days of Ciprofloxacin,in Complicated Urinary Tract Infections and Acute Pyelonephritis 3Five Days of LEVAQUIN(R) as Effective as 10 Days of Ciprofloxacin,in Complicated Urinary Tract Infections and Acute Pyelonephritis 4Data Presented at ASH Demonstrate Nebivolol Lowers Blood Pressure,as Long-Term Monotherapy and in Combination Therapy 2Data Presented at ASH Demonstrate Nebivolol Lowers Blood Pressure,as Long-Term Monotherapy and in Combination Therapy 3Data Presented at ASH Demonstrate Nebivolol Lowers Blood Pressure,as Long-Term Monotherapy and in Combination Therapy 4
(Date:5/24/2013)... 2013 With Memorial Day Weekend upon us, ... is offering tips to help prevent grill fires throughout ... Association (NFPA) reports that gas grills led to an ... or other solid-fueled grills, meanwhile, caused approximately 1,200 home fires ... Amica Insurance is sharing the following tips from the NFPA ...
(Date:5/24/2013)... 2013 E-Dentists.com has announced the launch ... JD Media Surge, a leading medical Internet marketing agency. ... analysis service will focus on providing dentists the help ... for their competitive keywords. The dental SEO analysis covers ... based on what their competitors are doing right. The ...
(Date:5/24/2013)... Drugs commonly used to treat glaucoma may cause droopy ... vision, according to a new study. The drugs, ... reduce eye pressure, have already been shown to cause ... researchers said, suggesting that the new findings could lead ... be conservative when prescribing these drugs, the researchers added, ...
(Date:5/24/2013)... highly respected Alzheimer,s researchers failed to replicate what appeared ... brain disease when they were published last year in ... online Feb. 9, 2012, suggested that the drug bexarotene ... beta amyloid plaques (Aβ) a pathological hallmark of ... to the authors of the 2012 report, drug treatment ...
(Date:5/24/2013)... York (PRWEB) May 24, 2013 The ... involving Intuitive Surgical Inc.’s da Vinci Surgical System ... court records, a Washington State Court jury ruled in ... in training a surgeon who performed a da Vinci ... The patient’s family had alleged in their lawsuit ...
Breaking Medicine News(10 mins):Health News:Don’t Get Burned: Five Grilling Tips from Amica Insurance 2Health News:Dental SEO Analysis Launched by E-Dentists.com in Partnership with JD Media Surge 2Health News:Common Glaucoma Drug May Cause Droopy Eyelids, Study Finds 2Health News:Multiple research teams unable to confirm high-profile Alzheimer's study 2Health News:Multiple research teams unable to confirm high-profile Alzheimer's study 3Health News:Da Vinci Robot Lawsuit News: Bernstein Liebhard LLP Comments on Verdict in Nation’s First Trial Involving Alleged Da Vinci Complications 2Health News:Da Vinci Robot Lawsuit News: Bernstein Liebhard LLP Comments on Verdict in Nation’s First Trial Involving Alleged Da Vinci Complications 3
... Facial expressions convey strong cues for someone,s emotional ... crucial in social interaction. This ability is known to ... as social anxiety or Korsakoff,s syndrome. New research has ... also characterized by changes in the way the brain ...
... 16 (HealthDay News) -- Many women in the United States ... due to dangerous ingredients, a new study indicates. Pai ... which are banned in the United States because they increase ... U.S. Food and Drug Administration announced a recall of Pai ...
... exercise routine means being able to overcome the obstacles ... the confidence that you can do it, researchers report. ... abilities increase this "situation-specific self-confidence," a quality the researchers ... self-efficacy to every single health behavior you can think ...
... You might want to take a pass on that nightcap, ... hinders the restorative functions of sleep. The findings, from ... in the November print issue of the journal Alcoholism: ... sleep appears linked to a disruption in nervous system function. ...
... , MONDAY, Aug. 15 (HealthDay News) -- ,Just 15 minutes ... by 14 percent and increase your life expectancy by three years, ... do at least 150 minutes, or a total of 1.5 hours, ... that doing even half that -- 15 minutes daily is about ...
... public standards incorporating new tests for impurities as well ... of over-the-counter (OTC) ingredients and products will be key ... co-sponsored by the U.S. Food & Drug Administration (FDA) ... addition to providing updates on new standards for acetaminophen ...
Cached Medicine News:Health News:Reduced recognition of fear and sadness in post-traumatic stress disorder 2Health News:U.S. Women Using Dangerous Weight-Loss Pill 2 Years After Recall 2Health News:Want to keep your exercise resolutions? New research offers pointers 2Health News:Want to keep your exercise resolutions? New research offers pointers 3Health News:More Evidence That Alcohol Hinders Good Sleep 2Health News:A Little Exercise Goes a Long Way to Cut Disease, Death Risk 2Health News:FDA-USP workshop to preview updated OTC standards 2Health News:FDA-USP workshop to preview updated OTC standards 3
... Mixevac® III represents the latest in advanced ... mixes all types of bone cement safely and ... system ensures the blades scrape the bowl whether ... superior mix. , ,The new bowl ...
... Tobramycin is the original Simplex™ ... the addition of 1g of ... formula, surgeons can expect the ... P Bone Cement, while ensuring ...
... Blood Flow Analyzer is a fast, clinically ... diagnosis of low and normal-tension glaucoma., ,The ... fast, clinically proven measurement that improves detection ... the management of glaucoma, and detection of ...
... Insertion/Removal ,The Mackool Cataract Support ... to the lens capsule and enclosed ... of zonular status. Insertion is ... retractors), and removal is accomplished in ...
Medicine Products: